Janssen Research & Development, LLC (JRD) is the research and development division of Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson. Headquartered in Raritan, New Jersey, it focuses on discovering and developing innovative pharmaceutical products to address unmet medical needs.
Established through the evolution of Janssen's research efforts—originally founded in 1953 by Dr. Paul Janssen in Belgium and acquired by Johnson & Johnson in 1961—JRD conducts global R&D across key therapeutic areas, including neuroscience, oncology, immunology, infectious diseases and vaccines, and cardiovascular & metabolic diseases.
The organization leverages advanced technologies such as genomics, biotechnology, biomarkers, and the microbiome to advance precision medicine, disease prevention, and novel treatments. With facilities in the US, Europe, and Asia, JRD supports a robust pipeline aimed at improving patient outcomes worldwide.
None yet. When a new project in the record names Janssen Research & Development, LLC as owner, partner or investor, it shows here.
Network meta-analysis of 10 trials found an adjunctive atypical antipsychotic superior on MADRS change, response, remission and CGI‑S, with no significant weight gain and favorable tolerability.
